Why did Neuland Laboratories (NEULANDLAB) stock move recently?

On 8/6/2026, Neuland Laboratories moved +8.2% — Neuland Laboratories hit a fresh record high after reporting a sharp jump in Q1 FY27 net profit (to roughly Rs 148 crore, up multi-fold YoY). This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Neuland Laboratories (NEULANDLAB) overvalued or fairly valued?

MarketChacha shows Neuland Laboratories's valuation in context — a forward P/E of about 46.1, a price-to-book of about 15.5 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Neuland Laboratories's revenue?

Neuland Laboratories reported revenue of ₹2,023 Cr for FY2026, with net profit of ₹363 Cr, per official filings.

What is the share price of Neuland Laboratories (NEULANDLAB)?

Neuland Laboratories last traded at ₹22,640.00 (-1.1% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

Neuland Laboratories

NEULANDLAB · NSE · Pharma · India

Snapshot

TickerNEULANDLAB

ExchangeNSE

SectorPharma

IndustryDrug Manufacturers - Specialty & Generic

CountryIndia

Employees2,183

HeadquartersHyderabad, India

Websitewww.neulandlabs.com

Filings tracked3

About Neuland Laboratories

Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, generic drug substances, as well as peptide APIs and synthesis services. The company serves generic companies, regional and domestic pharmaceutical manufacturers, distributors, and other pharmaceutical and biotechnology companies. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Who owns it

Promoters37.7%
Institutions28.2%
Public & other34.0%

70 institutional holders

Ownership breakdown from public market data. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Net margin trend6.7% → 17.9%

Margin has expanded by about 11.2 points — the business is getting more profitable.

Growth qualityrev 21% · PAT 54%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (BSE (official results filing)). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev ₹520 Cr · EPS 63.84

Est. earnings growth +101.9%

Next fiscal year

Rev ₹2,927 Cr · EPS 490.83

Est. earnings growth +32.8%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: BSE (official results filing)

Annual

Quarterly · last 6

Revenue (FY2026)

₹2,023 Cr

Net margin

17.9%

Revenue CAGR (4y)

+20.8%

Profit CAGR (4y)

+54.4%

EPS (FY2026)

283.01

Net profit (FY2026)

₹363 Cr

Ask MarketChacha about NEULANDLAB

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Aug 6, 2026
Neuland Laboratories hit a fresh record high after reporting a sharp jump in Q1 FY27 net profit (to roughly Rs 148 crore, up multi-fold YoY).
source 1 ↗source 2 ↗· confidence: high
Aug 5, 2026
Neuland Laboratories shares rose on the day its board was scheduled to approve Q1 FY27 results, with no other specific catalyst identified in recent coverage.
· confidence: low
Jul 29, 2026
No clear company-specific catalyst identified for the move; the stock rose alongside broader pharma sector momentum and recent positive analyst notes from prior weeks.
· confidence: low

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin
FY2026	₹2,023 Cr	₹363 Cr	283.01	17.9%
FY2025	₹1,477 Cr	₹260 Cr	—	17.6%
FY2024	₹1,559 Cr	₹300 Cr	—	19.3%
FY2023	₹1,191 Cr	₹164 Cr	—	13.7%
FY2022	₹951 Cr	₹64 Cr	—	6.7%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
Q1 FY27	₹642 Cr	₹148 Cr	—	23.0%
Q4 FY26	₹776 Cr	₹213 Cr	165.65	27.4%
Q3 FY26	₹440 Cr	₹41 Cr	—	9.2%
Q2 FY26	₹514 Cr	₹97 Cr	—	18.8%
Q1 FY26	₹293 Cr	₹14 Cr	—	4.7%
Q4 FY25	₹328 Cr	₹28 Cr	—	8.5%

Figures as reported, in ₹ (crore). Source: BSE (official results filing).

Filings & announcements

2026

Credit Rating
Announcement under Regulation 30 (LODR) - Credit Rating
BSE8/25/2026material
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Malabar India Fund Ltd
BSE8/17/2026
Intimation Under Regulation 30 Of SEBI Listing Regulations
Intimation under Regulation 30 of SEBI Listing Regulations
BSE7/31/2026

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.